The Food & Drug Administration recently gave a big green light to AlertWatch, which will get the Ann Arbor-based startup on the trial to cash-flow positive.
AlertWatch is developing patient-monitoring software to hospitals. The platform helps anesthesiologists monitor patients in the operating room, aggregating data from physiological monitors, anesthesia records, lab results and medical history to produce a dynamic real-time display of a patient's condition. The software determines whether things are normal, marginal or abnormal. The FDA gave it clearance earlier this month.
"If we didn't get that we'd be in in a pretty tricky situation," says Justin Adams, CEO of
AlertWatch. "It is the major milestone for our product."
The 2-year-old startup has doubled its staff to four employees over the last year, hiring a developer and a technical writer. AlertWatch’s technology is currently being used in three pilot programs, including one that has analyzed more than 17,000 surgeries at the
University of Michigan Health System.
"We're starting to get the word out and get some installs going," Adams says. "We're starting to create some revenue."
Source: Justin Adams, CEO of AlertWatch
Writer: Jon Zemke
Read more about Metro Detroit's growing entrepreneurial ecosystem at SEMichiganStartup.com.
Enjoy this story?
Sign up for free solutions-based reporting in your inbox each week.